Such simultaneous augmentation suggests that the lipid demand for cell growth and proliferation of lung cancer is huge, and probably neither of them alone can meet the need, as fatty acid synthase inhibitor treatment is generally harmful to cancer cells [27,28]. The gene discussed is FASN; the disease is cancer.